Difference between revisions of "Template:SwitchMAO"
From Psychiatrienet
| Line 2: | Line 2: | ||
*Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension. | *Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension. | ||
*Known side effects in fenelzine are oedema and/or increased liver enzyme levels. | *Known side effects in fenelzine are oedema and/or increased liver enzyme levels. | ||
| − | * It is adviced to admit the patient in a mental health care clinic for intensive monitoring during this switch.<ref>van den Eynde | + | * It is adviced to admit the patient in a mental health care clinic for intensive monitoring during this switch.<ref>Richtlijn voor het gebruik van klassieke MAO-remmers |
| + | van den Eynde Psyfar 2023 nr2</ref> | ||
Revision as of 16:24, 14 April 2026
- Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch. In addition, monitoring of sodium levels is adviced.[1]
- Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension.
- Known side effects in fenelzine are oedema and/or increased liver enzyme levels.
- It is adviced to admit the patient in a mental health care clinic for intensive monitoring during this switch.[2]
